Lineage, Inc. Common Stock (LINE)vsThe Southern Company JR 2017B NT 77 (SOJC)
LINE
Lineage, Inc. Common Stock
$37.75
+0.96%
REAL ESTATE · Cap: $9.50B
SOJC
The Southern Company JR 2017B NT 77
$19.10
+0.47%
REAL ESTATE · Cap: $21.79B
Smart Verdict
WallStSmart Research — data-driven comparison
SOJC leads profitability with a 0.0% profit margin vs -3.1%. LINE earns a higher WallStSmart Score of 35/100 (F).
LINE
Avoid35
out of 100
Grade: F
SOJC
Avoid21
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.8% revenue growth
0.0% earnings growth
Operating margin of 3.7%
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SOJC
SOJC has a balanced fundamental profile.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SOJC
The primary concerns for SOJC are Revenue Growth, EPS Growth, Profit Margin. Debt-to-equity of 1.95 is elevated, increasing financial risk.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SOJC is a value play — different risk/reward profiles.
LINE is growing revenue faster at 0.8% — sustainability is the question.
LINE generates stronger free cash flow (186M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LINE scores higher overall (35/100 vs 21/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →The Southern Company JR 2017B NT 77
REAL ESTATE · REIT - RESIDENTIAL · USA
The Southern Company is dedicated to the generation, transmission and distribution of electric power. The company is headquartered in Atlanta, Georgia.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?